Development of transdermal absorption enhancers

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K19936
• Research Category: Grant-in-Aid for Challenging Research (Exploratory)
• Allocation Type: Multi-year Fund
• Review Section: Medium-sized Section 90:Biomedical engineering and related fields
• Research Institution: Osaka University
• Principal Investigator: Kondoh Masuo 大阪大学, 大学院薬学研究科, 教授 (50309697)
• Project Period (FY): 2022-06-30 – 2024-03-31
• Keywords: 経皮吸収 / 皮膚バリア

Outline of Final Research Achievements

In this study, based on the results of preliminary research, we reconsidered the innovative tight junction (TJ) modulator/binder technology from the perspective of skin barrier control. Our aim was to develop a technology for skin shield control that could contribute to the transdermal delivery of pioneering biopharmaceuticals. We tackled this challenge and achieved the following four results: Identification of the key proteins constituting the TJ shield that play a role in the skin barrier, Construction of a search system for active substances that regulate the expression of these proteins, Identification of multiple candidate molecules that regulate the expression of these proteins, and Isolation of several molecules with activities that either attenuate or strengthen the barrier. These results are expected to serve as foundational technology for the transdermal administration of biopharmaceuticals

Free Research Field

薬物送達学

Academic Significance and Societal Importance of the Research Achievements

本研究では、予備検討の結果を踏まえ、独自かつ随一のTJ modulator/binder技術を皮膚バリア制御の観点から捉え直し、画期的バイオ医薬シーズの経皮投与に資する皮膚シールド制御技術の開発に挑戦し、複数の皮膚シールド制御分子候補を得た。この成果は、経皮投与の積年の隘路であった皮膚バリア透過をはじめて克服するものであり、これまで注射による投与を余儀なくされていた核酸や環状ペプチド等の中分子医薬のみならず、経口投与されている全ての医薬品を貼る薬として製剤化する基盤技術となりうる。